10-Q: SelectQuote Faces DOJ Inquiry Amidst Mixed Q3 Results, Prioritizes Healthcare Services Growth

SelectQuote's Q3 2025 results reveal a revenue increase driven by pharmacy services, overshadowed by a DOJ investigation and a decline in Senior segment performance.

Summary

• SelectQuote's Q3 2025 revenue increased to $408.16 million, up from $376.4 million in Q3 2024, driven by a significant rise in pharmacy revenue.
• Pharmacy revenue surged to $185.27 million, a 54% increase, while commissions and other services revenue decreased by 13% to $222.89 million.
• The company reported net income of $26.02 million, compared to $8.55 million in the same period last year.
• A civil complaint was filed against the company by the U.S. Department of Justice on May 1, 2025, alleging violations of the False Claims Act related to historical marketing arrangements for Medicare Advantage plans.
• The company is vigorously defending itself and cannot predict the outcome or impact on its financial statements.
• The Senior segment experienced a decrease in revenue due to fewer approved policies, while the Life segment saw an increase.
• The Healthcare Services segment, including SelectRx, Population Health, and SelectPatient Management, continues to be a growth area for the company.
• The company has realigned its reportable segments for fiscal year 2025, with Auto & Home business now included in the 'All Other' category.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue increased overall, the DOJ investigation and Senior segment decline temper the positive aspects. The company's focus on Healthcare Services is a positive sign, but the legal uncertainty creates risk.

Positives

• Overall revenue increased by 8% due to strong growth in the Healthcare Services segment.
• Net income improved significantly compared to the same period last year.
• The Life segment experienced revenue growth.
• The company completed a $350.0 million Senior Non-Convertible Preferred Stock transaction, strengthening its financial position.
• The number of SelectRx members increased by 41%.

Negatives

• The U.S. Department of Justice filed a civil complaint against the company, creating uncertainty.
• Commissions and other services revenue decreased by 13%.
• The Senior segment experienced a decrease in revenue.
• The LTV per Medicare Advantage approved policy decreased by 8%.

Risks

• The ongoing legal proceedings with the DOJ could have a material adverse effect on the company's business, financial condition, and operating results.
• The company's reliance on a few major insurance carrier customers poses a concentration risk.
• Fluctuations in interest rates could impact the company's financial performance.
• The company's ability to maintain compliance with debt covenants is crucial for its financial stability.
• The company is currently in a three-year cumulative loss position.

Future Outlook

The company is focused on growing its Healthcare Services segment and managing its debt obligations. The company is vigorously defending itself against the DOJ complaint and cannot predict the outcome or impact on its financial statements.

Industry Context

The direct-to-consumer insurance distribution market is competitive, with companies like eHealth and GoHealth also vying for market share. SelectQuote's focus on technology and data analytics aims to differentiate it in this landscape. The increasing demand for Medicare Advantage plans and healthcare services among the aging population presents a significant growth opportunity.

Comparison to Industry Standards

• SelectQuote's revenue growth in the Healthcare Services segment is notable compared to traditional insurance distribution models.
• Companies like Humana and UnitedHealth Group (UHC) have vertically integrated healthcare services, while SelectQuote partners with various providers.
• eHealth, a competitor in the online insurance marketplace, also faces similar regulatory and compliance challenges.
• The LTV per approved policy is a key metric, and SelectQuote's decrease in this area warrants attention compared to industry benchmarks.

Legal Proceedings

• The company is defending itself against a civil complaint filed by the U.S. Department of Justice alleging violations of the False Claims Act.
• The company is involved in ongoing securities class action litigation (In re SelectQuote, Inc. Securities Litigation).
• The Jadlow v. Danker, et al. stockholder derivative action remains stayed.

Related Party Transactions

• SelectRx leases the Monaca facility from an Executive Vice President of SelectRx.

Stakeholder Impact

• Shareholders face uncertainty due to the DOJ investigation and potential financial impact.
• Employees may be affected by the company's cost management efforts and strategic shifts.
• Customers could be impacted by changes in service offerings or policy options.
• Insurance carrier partners may be affected by changes in SelectQuote's sales strategies and compliance practices.
• Creditors are exposed to risks related to the company's debt obligations and legal liabilities.

Next Steps

• The company plans to vigorously defend itself against the DOJ complaint.
• The company will continue to focus on growing its Healthcare Services segment.
• The company will continue to evaluate the realizability of its deferred tax assets.

Key Dates

Keywords

SelectQuote, revenue, pharmacy, Medicare Advantage, Senior, Healthcare Services, Life insurance, legal proceedings, DOJ, financial results, preferred stock, warrants, debt